MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2023 International Congress

August 27-31, 2023. Copenhagen, Denmark.

View by Title View Categories
Jump to:  View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z
  • Obesity is a protective factor for the development of Parkinson’s disease in participants of the Framingham Heart Study Cohort

    S. O'Shea, Y. Liu, C. Liu, S. Frank, R. Au (New York, USA)

  • Observations on 5 Parkinson’s patients taking Mucuna pruriens as natural source of levodopa

    S. Elsas (Arlesheim, Switzerland)

  • Obsessive-Compulsive symptoms in Parkinson’s Disease: beyond the Impulse Control Disorders

    D. Damas, M. Fernandes, I. Carvalho, C. Fernandes, A. Araújo, I. Cunha, J. Lemos, F. Moreira (Coimbra, Portugal)

  • Ocular microtremor in Parkinson’s Disease: Protocol for an observational pilot study

    L. Graham, R. Morris, R. Vitorio, S. Stuart, A. Godfrey, R. Walker, C. Mcdonald (Newcastle, United Kingdom)

  • Oculomotor changes in the premotor stage of LRRK2- G2019S associated Parkinson’s disease.

    M. Rivera Sánchez, C. Lage Martínez, A. Sánchez Rodríguez, M. Sierra Peña, I. González Aramburu, L. Manrique Arregui, MV. Sánchez Peláez, C. García Cena, A. Calvo Córdoba, J. Madera Fernández, J. Martín Arroyo, J. Infante Ceberio (Santander, Spain)

  • Oculomotor findings in paraneoplastic neurological syndromes with cerebellar ataxia

    A. Milovanović, I. Basta, N. Kresojević, O. Tamaš, A. Tomić Pešić, I. Stanković Tutuš, M. Svetel, VS. Kostić, NT. Dragašević Mišković (Belgrade, Serbia)

  • Oculomotor parameters measured during free viewing of video differentiate Parkinson’s disease from progressive supranuclear palsy

    H. Riek, B. White, D. Brien, B. Coe, C. Fearon, S. Arnott, D. Beaton, M. Binns, S. Black, E. Finger, A. Frank, D. Grimes, A. Lang, W. Lou, C. Marras, M. Masellis, P. Mclaughlin, J. Orange, A. Peltsch, A. Roberts, T. Steeves, K. Sunderland, B. Tan, D. Tang-Wai, C. Tartaglia, D. Munoz (Kingston, Canada)

  • Oh man: Why are males more prone to Musician’s Dystonia?

    J. Doll-Lee, E. Altenmüller, A. Lee (Hannover, Germany)

  • Olfactory and taste function in early Parkinson’s disease with mild cognitive impairment

    JJ. Lee, IH. Kwak, HI. Ma, YE. Kim (Anyang-si, Republic of Korea)

  • Olfactory discrimination ability is associated with subjective lack of social support in female Parkinson’s patients

    T. Blum, L. Consortium, R. Dodel (Essen, Germany)

  • Olfactory discrimination differentiate drug-induced parkinsonism and Parkinson’s disease

    IH. Kwak, JJ. Lee, MS. Kim, SY. Kang, HI. Ma, YE. Kim (Anyang-si, Republic of Korea)

  • Olfactory dysfunction and neuropsychiatric manifestations in early drug-naïve Parkinson’s disease

    P. Julayanont (Phoenix, USA)

  • Olfactory dysfunction as a predictor of the future development of parkinsonism in COVID patients

    M. de Rosa, D. Calisi, L. Bonanni, M. Onofrj (Chieti, Italy)

  • Olfactory neurons’ Substance P is highly expressed in Parkinson’s disease reflecting gastrointestinal dysfunction

    T. Schirinzi, D. Maftei, P. Grillo, R. Bovenzi, J. Bissacco, C. Simonetta, H. Zenuni, FM. Passali, S. Di Girolamo, A. Stefani, NB. Mercuri, R. Lattanzi, C. Severini (Rome, Italy)

  • Olfactory sniffing is altered in patients with Parkinson’s disease

    M. Andelman-Gur, N. Hezi, A. Ezra, J. Zitser, T. Gurevich, N. Sobel (Rehovot, Israel)

  • On-demand therapy (ODT) in Parkinson’s disease: a survey of advanced practice providers

    K. Papesh, A. Merriam, C. Zebendon (Phoenix, USA)

  • ON/OFF Non-Motor Evaluation: A New Way to Evaluate Non-Motor Fluctuations in Parkinson’s Disease

    F. Faggianelli, T. Witjas, JP. Azulay, I. Benatru, C. Hubsch-Bonneaud, M. Anheim, C. Moreau, E. Hainque, S. Drapier, B. Jarraya, C. Laurencin, D. Guehl, L. Hopes, C. Brefel-Courbon, M. Tir, A. Marques, T. Rouaud, D. Maltête, C. Giordana, K. Baumstarck, O. Rascol, JC. Corvol, AS. Rolland, D. Devos, A. Eusebio (Marseille, France)

  • Online education to promote compensation strategies for gait impairments in underserved Parkinson populations

    T. Capato, A. Tosserams, B. Bloem, J. Nonnekes (São Paulo, Brazil)

  • Online recruitment and retention in the Parkinson’s Progression Markers Initiative (PPMI)

    C. Tanner, E. Brown, L. Chahine, D. Weintraub, R. Dobkin, W. Poewe, E. Tolosa, C. Marras, S. Schade, C. Coffey, M. Korell, C. Stanley, J. Valdeverde Twiggs, M. Kuhl, K. Fabrizio, S. Chowdhury, T. Sherer, A. Siderowf, T. Simuni, K. Marek (SAN FRANCISCO, USA)

  • Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease

    V. Fung, J. Aldred, F. Bergquist, E. Danielsen, A. Jeong, J. Jia, A. Spiegel, S. Talapala, C. Carroll (Westmead, Australia)

  • Operationalising goal setting as an outcome measure: Experience from the PRIME-UK randomised controlled trial

    E. Tenison, K. Lloyd, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

  • Opicapone versus entacapone: Head-to-head comparison of Healthcare Resource Utilisation in COMT-I naïve People with Parkinson’s

    G. Harrison-Jones, L. Marston, F. Morgante, K R. Chaudhuri, G. Castilla-Fernández, V. Di Foggia (Windsor, United Kingdom)

  • Opicapone’s Effects on Progression Scales in Relation to the 9-Symptom Wearing-off Questionnaire: the OPTIPARK Study

    D. Martins, A. Lees, H. Reichmann, J-F. Rocha (Coronado, Portugal)

  • Opsoclonus Myoclonus Syndrome due to subdural hematoma: an uncommon etiology

    V. Arca, F. Cavalcante, M. Saraiva, M. Bezerra (Recife, Brazil)

  • Optimal topographic characteristics of focused ultrasound unilateral thalamotomy for tremor-dominant Parkinson´s disease

    E. Natera-Villalba, JA. Pineda-Pardo, M. Del álamo, M. Matarazzo, R. Rodríguez-Rojas, R. Raimundo, R. Martínez-Fernández, JA. Obeso (Madrid, Spain)

  • Optimizing DBS in PD: Investigating LFP beta power fluctuations in response to chronic stimulation

    S. Pitts, J. Jimenez-Shahed (New York, USA)

  • Orthostatic hypotension and frailty

    A. Ovchynnykova, E. Trufanov (Kyiv, Ukraine)

  • Orthostatic hypotension exacerbates gray matter atrophy related to REM sleep behavior disorder in de novo Parkinson’s disease

    T. Shiraishi, T. Umehara, Y. Iguchi (Tokyo, Japan)

  • Orthostatic vital sign changes do not influence 5-year motor outcomes in PD

    J. Li, J. Ruiz Tejeda, D. Tran, S. Nguyen, N. Phielipp (Irvine, USA)

  • Outcomes From Genetic Testing in a UK Movement Disorder Clinic

    H. Morrison, L. Leemet, I. Berry, M. Boca (Bristol, United Kingdom)

  • Outcomes of Focused Ultrasound Thalamotomy in Tremor Syndromes

    J. Peters, J. Maamary, K. Kyle, N. Olsen, L. Jones, S. Bolitho, Y. Barnett, B. Jonker, S. Tisch (Darlinghurst, Australia)

  • Outcomes of patients treated with staged bilateral MRgHIFU thalamotomy using four-tract tractography targeting for medically refractory Essential Tremor

    N. Saez Calveras, D. Imphean, V. Sharma, L. Lanford, J. Viera, P. O'Suilleabhain, B. Shah (Dallas, USA)

  • Overlapping Pathogenetic Findings in Developmental Coordination Disorder (DCD), Ataxia, Dystonia and Myoclonus: is DCD part of a Movement Disorder Spectrum?

    M. Garofalo, F. Vansenne, D. Sival, D. Verbeek (Groningen, Netherlands)

Jump to:  View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley